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The RASSF family of proteins has been extensively studied in terms of their genetics, structure and function. One of the functions
that has been increasingly studied is the role of the RASSF proteins in the DNA damage response. Surprisingly, this research, which
encompasses both the classical and N-terminal RASSF proteins, has revealed an involvement of the RASSFs in oncogenic pathways
as well as the more familiar tumour suppressor pathways usually associated with the RASSF family members. The most studied
protein with respect to DNA damage is RASSF1A, which has been shown, not only to be activated by ATM, a major regulator of
the DNA damage response, but also to bind to and activate a number of diﬀerent pathways which all lead to and feedback from the
guardian of the genome, p53. In this review we discuss the latest research linking the RASSF proteins to DNA damage signalling
and maintenance of genomic integrity and look at how this knowledge is being utilised in the clinic to enhance the eﬀectiveness of
traditional cancer therapies such as radiotherapy.
1.Introduction
RASSF proteins were originally designated on the basis of
sequence homology to domains that associate with Ras-like
small GTP-binding proteins. These domains are known as
Rasassociation(RA)domains[RalGDS(Ralguaninenucleo-
tide dissociation stimulator)/AF6 (ALL-1 fusion partner
from chromosome 6)] and are distinct from Ras-binding
domains (RBD) which bind an alternative set of Ras eﬀectors
[1, 2]. Ras belongs to a family of small G-proteins that are
ubiquitously expressed and oscillate between an inactive,
GDP-bound state, and an active, GTP-bound state, in re-
sponse to diverse cellular signals. Various GTP-bound Ras-
like proteins bind eﬀector proteins to mediate distinct bio-
logical responses. There are 150 Ras-like proteins encoded in
the human genome which can be grouped by homology or
functionality, as being similar to Ras, Rho, Rab, Arf (ADP-
ribosylation factor), or Ran. While originally suggested to
associate with Ras [3], the RASSF family has a diﬀerential af-
ﬁnity for Ras-like GTPases, with NORE1 (RAPL/RASSF5)
displaying a much greater aﬃnity for the closely related Ras
homolog, Rap1B, than H-Ras itself [4]. The RA domain of
RASSF1 associates with K-Ras, rather than H-Ras or N-Ras
and is also described to associate with Ran [5, 6]. There are
now 10 members in the RASSF family (RASSF1-10) subdi-
vided into two distinct subgroups, the classical RASSF pro-
teins (RASSF1-6) and the N-terminal RASSF proteins
(RASSF7-10) based on the location of the RA domain [7].
Little is known about the GTP-binding proteins that may
interact with the majority of the RASSF family or how they
function but the potential exists for a greater number of sig-
nalling connections. In addition to an RA domain, the clas-
sical RASSF proteins also have a protein-protein interaction
motif known as the SARAH domain that is responsible for
scaﬀolding and regulatory interactions [8]. This domain is
a short coiled-coil region and so named due to its location in
the extreme C-terminus of genetically linked Drosophila
proteins; Salvador (hSav1/WW45), dRASSF and Hippo
(hMST1/2) (SARAH: SAlvador, RAssf, Hippo) which can
form both homo- and heterodimers [9]. The N-terminal
RASSFs lack an identiﬁable SARAH domain, although the
SMART database predicts that RASSF7, 8 and 10 contain ex-
tensive coiled-coil regions, which can dimerise [10].
RASSF1Aand RASSF5A[alsoknown asNORE1A(Novel
Ras Eﬀector 1 isoform A)] also contain an N-terminal atypi-
cal diacylglycerol/phorbol ester-binding (DAG) domain also2 Molecular Biology International
knownastheproteinkinaseCconservedregion(C1)domain
that contains a central zinc ﬁnger (Zinc-binding domain)
[11]. The Zinc ﬁnger in the RASSF family members is
denoted “atypical” because it lacks critical residues required
for binding of phorbol esters or DNA and therefore probably
mediates protein-protein interactions. Indeed, structural
analysis indicates that the C1 domain of NORE1A associates
with the RA domain to occlude RAS association [12]. As
none of the family members have any known enzymatic
activity they are thought to be scaﬀold/adaptor proteins us-
ing these binding domains to bring target proteins together
to impart their functions.
There are a number of reviews that introduce the RASSF
family and the pathways within which they function; how-
ever,thispaperwillfocusontheemergingrolesoftheRASSF
family and their eﬀectors in the response to DNA damage.
The best described protein in this family with respect to
DNA damage is RASSF1 thus the review will concentrate on
this protein with particular reference to a recently elucidated
signalling network from RASSF1A and the potential clinical
signiﬁcance of targeting this pathway [13].
2. RASSF1
It had long been suspected that the 3p21.3 region of the
human genome harboured one or more important tumour
suppressors because loss of heterozygosity (LOH) was found
at this locus in lung, breast, and kidney tumours and gene-
tic instability in this region is the earliest most frequently de-
tected deﬁciency in lung cancers [14–20]. This 120kb region
contains 8 genes namely CACNA2D2, PL6, 101F6, NPRL2/
G21, ZMYND10/BLU, RASSF1/123F2, FUS1, and MYAL2.
However, none of these candidate genes are frequently mu-
t a t e di nc a n c e r s[ 16, 21]. At the same time as these LOH
studies, Dammann et al. identiﬁed RASSF1 as an interacting
partner of the DNA damage repair protein xeroderma pig-
mentosum complementation group A (XPA) [22]. While the
role of RASSF1 in nucleotide excision repair could not be
veriﬁed, it may yet prove to be signiﬁcant given the emerging
role of RASSF1 in the DNA damage response. The RASSF1
gene consists of 8 exons spanning a region of about 11kb.
The C-terminal showed high-sequence homology with
NORE1, containing an RA domain and thus the gene was
named RASSF1 for Ras association domain family member 1
[22]. Alternative splicing generates 8 isoforms A–H from
promoters held within 2 CpG islands. The ﬁrst CpG island
encompasses the promoter regions for RASSF1A, D, E, F,
and G. Epigenetic inactivation by DNA methylation at this
CpG island is one of the most common events in human
cancers (reviewed in [23–25]). This methylation has recently
beenattributedtoHOXB3drivenoverexpressionoftheDNA
methyltransferase, DNMT3B [26]. RASSF1B, C, and H are
generated from a promoter located within the larger 3  CpG
island [27]. This commonly remains unmethylated in can-
cers and consequently cells retain expression of these iso-
forms[23].RASSF1AandRASSF1Carethemajortranscripts
oftheRASSF1geneandareexpressedubiquitouslyinnormal
tissues [28].
3. RASSF1A
ExogenousexpressionofRASSF1Areducescolonyformation
in soft agar and reduced tumourigenicity in nude mice [22,
29–31]. Similarly, reexpression of RASSF1A using demethyl-
transferaseinhibitors suchaszebularine and5-aza-2 -deoxy-
cytidine caused signiﬁcant growth arrest in ovarian cancer
celllines[32].Reciprocally,RASSF1Aknockoutmicedevelop
spontaneous tumours, particularly when combined with a
knockout of p53, highlighting the signiﬁcance of RASSF1A
in tumour development [33–35]. In addition these
RASSF1A−/−,p 5 3 −/− m i c es h o w e dh i ghl e v e l so fa n e u p l o i d y /
tetraploidy suggesting an important role for RASSF1A in
maintaining genomic integrity. RASSF1A has been shown to
have many roles in cell cycle control and microtubule organ-
isation [23, 27], the response to DNA damage is, however,
only beginning to be elucidated. It is therefore timely to pre-
sent these pathways and highlight their importance to the
DNA damage response, genomic integrity, and cell survival
during cancer development.
4. RASSF1 Phosphorylation
The majority of the phosphorylation of RASSF1A has being
attributed to the phosphorylation of Serine 202/203. These
sites have been demonstrated to be targeted by a number
of kinases including, both CDK (Cyclin-Dependent Kinase)
and Aurora kinases [36–40]. These phosphorylation events
prevent the association of RASSF1A with microtubules dur-
ing prometaphase. The phosphorylation of RASSF1A on
these sites also coordinates the regulation of mitosis by con-
trolling activation of the anaphase-promoting complex/
cyclosome (APC/C), and regulation of syntaxin16 to pro-
mote cytokinesis [39, 40]. Loss of phosphorylation at these
sites leads to defects in mitosis resulting in aneuploidy and
genomic instability.
In the DNA damage response phosphorylation of
RASSF1A serine 131 (S131) is emerging as an important
phosphorylation site. The initial kinases that respond to
breaks in DNA are the phosphatidyl-inositol 3-kinase like
kinases ATM (Ataxia Telangiectasia Mutated), ATR (ATM-
andRad3-Related),andDNA-PKcs (DNA-dependentprotein
kinase catalytic subunit) [41]. RASSF1A has a consensus site
for ATM phosphorylation on serine 131 that is conserved
in vertebrates and unique amongst family members and
has recently been conﬁrmed as a bone-ﬁde target for ATM
[13, 42]. Serine 131 phosphorylation appears important for
RASSF1A activation and inactivating mutations of this site
have been identiﬁed in human cancers [43]. Indeed Shivaku-
mar et al., showed that mutation of the predicted phospho-
rylation site, S131F, removed the ability to induce cell cycle
arrest and block cell proliferation [43]. ATM-dependent
phosphorylation at the 131 site is also restricted by S131F
and disables the ability of RASSF1A to respond to various
DNA-damagingagents[13].MutationsneartheATMsiteare
hypothesised to function by inactivating ATM phosphory-
lation. One of these is a nonsynonymous single nucleotide
polymorphism (SNP) at p.RASSF1A-A133S (rs2073498),Molecular Biology International 3
C1 RA SARAH
Polymorphism SQS
WT sequence ETPDLSQAE
ATM phosphorylation site
Mutant serine
MST1/2 and Ras/Ran
binding.
MOAP-1 and
MDM2 binding
RASSF1A
RA SARAH
∗
∗
DAXX binding
101 195 288 290 340
1
126 134
125 218 220 270
RASSF1C
51 1
FQA
56–64
Amino acid
Amino acid
Salvador binding.
Figure 1: Cartoon depicting the interactions of RASSF1A and RASSF1C. RASSF1A and RASSF1C share a common C-terminal aminoacid
sequence, which includes the ATM phosphorylation site (red asterisk), the RA domain, and the SARAH domain but diﬀers at the N-
terminal. RASSF1A has a C1 domain which interacts with MOAP-1 and MDM2. RASSF1C lacks the C1 domain but has an alternative
DAXX interaction domain. Serine 131 of RASSF1A has been shown to be mutated from serine (S) to phenylalanine (F). An alanine (A) to
Serine (S) polymorphism also exists at the 133 site.
which has signiﬁcant allele frequencies in human popula-
tions(http://hapmap.ncbi.nlm.nih.gov/).Theminor alleleof
theSNPencodesaserine(A133S)anddecreasestheabilityof
RASSF1A to become phosphorylated which, like S131F,
r e s u l t si nad e f e c t i v eG 1a r r e s t[ 43]. This suggests that
sequence changes to the ATM consensus sequence (amino-
acids125–138)mayseverelyinhibitthefunctionofRASSF1A
by disrupting the phosphorylation of S131 and preventing
the activation of RASSF1A (Figure 1).
RASSF1A association with Ran directs the formation of
a Ran-GTP gradient between the spindle poles and the meta-
phase plate which is important for the formation of mitotic
spindle and for successful completion of mitosis. RASSF1A
targetsMST1/2kinaseactivitytowardstheRanGEF(GTPex-
change factor) RCC1, which inhibits its function and results
inelevatedRan-GTPnearthemetaphaseplate.Takentogeth-
er, these studies indicate that RASSF1A is important for the
maintenance of genomic stability by acting as an integrity
checkpoint factor. Loss of RASSF1A is likely to weaken the
prometaphasecheckpointandincreasethepotentialtocreate
genomic instability and DNA damage leading to cancer de-
velopment. Indeed, the restriction of RASSF1A activity by
modulation of the ATM site may be linked to numerous ob-
servations regarding the early onset of tumours in indivi-
duals carrying one minor allele of the p.RASSF1A-A133S
polymorphism [44, 45]. This has been controversially linked
totheexacerbation ofaBRCA1/2 genomicinstability pheno-
type; however, the inconsistency may be due to confounding
factors other than BRCA2 and may be due to genomic in-
stability via defects in RASSF1A itself [46]. All this may indi-
cate that DNA damage activation of RASSF1A may provide
an extra level of regulatory response, whereby the prometa-
phasecheckpointsensescellsenteringintomitosiswithDNA
damage.
5. Regulation by Domain Interaction
As a scaﬀold, RASSF1A must exert its tumour suppressor
function through its interaction domains. The two most
importantdomainsinthecontextofDNAdamagearetheC1
domain and the SARAH domain. The most signiﬁcant bind-
ing partnersidentiﬁed tointeractwiththeC1domain arethe
TNF-R1/TRAIL-R1—Modulator of Apoptosis-1 (MOAP-1)
complexes and the MDM2/DAXX/HAUSP/p53 complex [47,
48]( Figure 1). MOAP-1 and RASSF1A are recruited to either
TNF-R1 or TRAIL-R1 in response to TNFα stimulation.
RASSF1A binds MOAP-1 causing an activating conforma-
tional change to the structure of MOAP-1. The active struc-
ture can bind to the proapoptotic Bcl-2 family member BAX
which creates a pore in the outer mitochondrial membrane
leading to the release of cytochrome C and induction of cas-
pase-dependent apoptotic signalling pathways [47, 49]. BAX
andtheassociatednegativeregulatorBAKtightlyregulatethe
cell’s response to apoptotic signals and are often coordinated
with other apoptotic signals such as DNA damage. It is rea-
sonable to assume that RASSF1A-MOAP-1 may be aﬀected
by DNA damage but whether this contributes to the regula-
tion of BAX/BAK at the mitochondria remains uncertain.
The response of tumour suppressor p53 to DNA damage
r e s u l t si nav a r i e t yo fo u t c o m e si n c l u d i n gc e l lc y c l ea r r e s t ,
apoptosis,andsenescence,combiningtoprotecttheintegrity
of the genome [50, 51]. In unstressed cells p53 levels are low,
beingcontrolledbytheRINGdomain-containing E3ubiqui-
t i nl i g a s eM D M 2( M o u s eD o u b l eM i n u t e2 )[ 52, 53]. Induc-
tionofDNAdamageresultsinphosphorylationofp53bythe
DNA damage checkpoint proteins ATM (on serine 15) and
CHK2 (Checkpoint Kinase 2) (on serine 20) [54, 55]. These
phosphorylation events combine with an ATM-mediated re-
striction of MDM2 activity to stabilize p53. Song et al. have4 Molecular Biology International
recentlyshownthattheC1domainofRASSF1Acanbindand
sequester MDM2 in an ATM-dependent manner [48]. They
describe a complex consisting of MDM2, DAXX (death-do-
main-associated protein), and HAUSP1 (a deubiquitinating
enzyme). HAUSP1 removes ubiquitin molecules from
MDM2 and increases its stability. Upon DNA damage, ATM
activates RASSF1A driving its association with MDM2,
potentially through phosphorylation at S131. RASSF1A dis-
rupts the MDM2-DAXX-HAUSP1 complex, sequestering
MDM2 away from p53, and preventing HAUSP1-regulated
deubiquitination of MDM2 promoting its degradation. Re-
lease of DAXX from the complex is thought to allow DAXX
relocation to the plasma membrane where it can bind the
death receptor Fas and activate c-Jun NH2-terminal kinase
(JNK) [56]. Activated p53 exerts its tumour suppressor func-
tion by acting as a transcription factor. It has recently been
shown that the RASSF1 promoter is a target for p53 [57].
Interestingly, p53 appears to downregulate the transcription
of RASSF1A hinting at a second mechanism through which
p53 can negatively regulate itself in addition to the upregula-
tion of MDM2.
RASSF1A makes two signiﬁcant interactions through its
SARAH domain; the ﬁrst with mammalian sterile 20-like
kinases 1 and 2 (MST1/2) and the second to the scaﬀold pro-
tein Salvador (Figure 1). The RASSF1A interaction with
MST1/2 leads to an increase in the local concentration of
MST molecules allowing them to undergo transphosphory-
lation and autoactivation [58]. The interaction further sta-
bilises the MST1/2 kinase activity by preventing dephospho-
rylation of MST1/2 [59]. MST1/2 were initially cloned from
lymphoid cDNA library when looking for human relatives
of Saccharomyces cerevisiae protein Ste20 and subsequently
shown to be activated by a wide variety of cellular stresses
[60–63]. Of note is that both Drosophila dMST (Hippo) and
MST2 are activated in response to DNA damage. In mam-
mals, DNA damage induction of MST2 requires direct bind-
ing of RASSF1A- and ATM-mediated phosphorylation of
S131 [13, 64, 65]. Interestingly MST1 was shown to be able
toactivatep53inresponsetocisplatin-inducedDNAdamage
by phosphorylating and inactivating Sirt1, a deacetylase that
inactivates p53 [66]. Additional substrates of MST kinases
that may prove subject to DNA damage are the histones H2B
and H2AX, JNK and FOXO transcription factors [67–70].
However, a clear example of signalling through RASSF1A-
MST after DNA damage is the recruitment and activation of
the large tumour suppressor kinases 1 and 2 (LATS1/2)
[71, 72].
Studies on the Drosophila homolog of MST1/2, Hippo
have discovered that the pathway through Warts (LATS1) is
responsible for controlling proliferation and apoptosis and is
conserved in both vertebrates and invertebrates. Mutations
in pathway member’s Hippo (MST1/2), Warts (LATS1/2),
Salvador (WW45), or Mats (Mob1 as a tumour suppressor)
result in vast tissue overgrowth. The pathway generates a
signal to inhibit Yorkie (YAP). Yorkie mutants therefore
inevitably show a reduced tissue growth phenotype (review-
ed in [73]). Yorkie is a non-DNA binding transcriptional
coactivator that binds Scalloped (TEAD1-4) leading to the
upregulation of proteins such as Cyclin E and Diap-1 to
promote cell division and inhibit apoptosis. In this case
Warts phosphorylates Yorkie creating a site for 14-3-3 bind-
ing. This sequesters Yorkie in the cytoplasm inhibiting its
oncogenic activity [74]. In mammals, in the presence of
RASSF1AandaDNAdamagesignal,LATS1phosphorylation
ofYAPmaintainsapoolofYAPinthenucleuswhichswitches
binding partner from the antiapoptotic, YAP-TEAD com-
plex to a proapoptotic YAP-p73 complex [75]. The interac-
tion between YAP1 and p73 stabilises p73 by preventing its
nuclear export and subsequent degradation [76–78]. YAP1
functions as a coactivator of p73 and this complex upregu-
latesp73responsivegenessuchastheproapoptotic BH3only
Bcl-2 family member, PUMA [79, 80]. This idea is in agree-
ment with the ﬁnding that both LATS1 and LATS2 mediate
apoptosis through p53. In certain cases LATS2-mediated
apoptosis is p53 independent, potentially indicating a switch
to YAP1 and p73 [13, 81, 82].
LATS2 has been shown to activate p53 both directly, by
binding to and inhibiting MDM2 and indirectly by driving
the nuclear accumulation of ASPP1 (apoptosis-stimulating
protein of p53) [83, 84]. Interestingly, cytoplasmic ASPP1
appears to behave in an opposite manner and inactivates the
ability of LATS1 to interact with YAP1 [85]. As RASSF1A
activates LATS1/2 in response to DNA damage this could
potentially drive ASPP1 activation of p53 and contribute to
the overall p53 response. Interestingly the Drosophila ASPP
protein (dASPP) has also been shown to interact with
dRASSF8 to regulate C-terminal Src kinase (dCsk) and ad-
herens junctions [86], a site key to the regulation of the core
hippo pathway [87].
LATS2 has been implicated in the G1 tetraploidy check-
point, a process that is thought to be driven by LATS2 activa-
tion by ATR and leads to direct stabilisation of p53 [83, 88].
Active p53 then creates a positive feedback loop with LATS2
by upregulating its activity further [88]. In response to UV
radiation CHK1 activation by ATR has been shown to acti-
vate LATS2 [89].
Although not addressed in a RASSF1A-dependent man-
ner, YAP forms an additional DNA damage promoted com-
plex with the transcription factor early growth response 1
(EGR1) [90]. The interaction promotes enhanced transcrip-
tionalactivityofEGR1fortheBcl-2-associatedX(BAX)pro-
moter. Thus YAP can act as an oncogene and a tumour sup-
pressor in a RASSF1A-context-dependent manner.
In Drosophila dRASSF and Salvador are known to com
pete for MST binding. Here Salvador acts as an adaptor to
bring Hippo and Warts together to activate the hippo path-
way, which is antagonised by dRASSF [91]. In mammals,
however, RASSF1A can bind both MST1/2 and Salvador at
the same time using diﬀerent regions with the SARAH do-
main. Using an L308P mutant of RASSF1A that cannot bind
MST but remains bound to Salvador, Donninger et al. have
shown that the RASSF1A Salvador interaction can activate
p73 in an MST-independent manner [92].
6. RASSF1C
RASSF1Cisthesecondubiquitouslyexpressedisoformofthe
RASSF1 gene. Like RASSF1A, RASSF1C contains the ATMMolecular Biology International 5
consensussequence(Figure 1).Thissite,atSerine61,hasnot
yet been conﬁrmed but the sequence is identical between
RASSF1AandRASSF1Catthissitesoitisplausibletosuggest
that RASSF1C is also phosphorylated and activated by ATM.
Indeed, the Serine 61 to phenylalanine (S61F) mutant of
RASSF1C was unable to block the genomic destabilising
eﬀectsofRaswhichcanbeablatedbyoverexpressionofwild-
type RASSF1C in the embryonic kidney cell line 293T and
human lung tumour cell line NCI-H1299 [93]. This suggests
that DNA damage activation of RASSF1C may require phos-
phorylationofSerine61(RASSF1A-131)site.Furthertothis,
RASSF1C has recently been implicated in a DNA damage
response pathway involving DAXX (which also binds to
RASSF1A)andJNK[94](Figure 1).Inunstressedconditions
RASSF1C is shown to be in a complex with DAXX in the
nucleus, recently resolved by NMR [95]. Upon ultraviolet
radiation or MMS-induced DNA damage this interaction is
lost allowing RASSF1C to move to the cytoplasm where it
aidstheactivationofSAPK/JNKsignalling[94].DAXX,how-
ever, remains in the nucleus concentrating at PML bodies.
The signal that leads to release of RASSF1C from DAXX is
unknown; however, it would be interesting to see if the sig-
nal relies upon the ATM phosphorylation site. Conversely,
another study has identiﬁed that RASSF1C, far from being
activated by DNA damage, is targeted for degradation under
stress conditions. Exposure to UV radiation or treatment of
cells with doxorubicin leads to RASSF1C phosphorylation by
GSK3β creating a phosphodegron at S19/23 which is bound
tobySCFβ-TrCP targetingRASSF1Cfordegradation[96].This
GSK3β-dependent degradation was shown to be inhibited
by the PI3-K/AKT pathway. Since AKT activity can lead to
RASSF1Cupregulation itsuggeststhatRASSF1Ccouldfunc-
tion as an oncogene. This is in keeping with several recent
reports showing that RASSF1C increased cell proliferation
in lung cancer cells and migration in breast cancer cell lines
[97, 98].
7. Therapeutic Implicationsof RASSF1ALoss
One of the most common and widespread events to occur
during cancer development is the loss of RASSF1A expres-
sion. This loss is due to methylation of the upstream CpG
islands in the RASSF1 gene [22, 29]. The frequency of epi-
genetically driven loss of RASSF1A correlates well with the
increasing grade of the tumour. Methylation has been re-
ported in over 37 tumour types (comprehensively reviewed
in [24, 99]) and is thought to be an early event in breast and
thyroid tumourigenesis, childhood neoplasia, and endome-
trial carcinogenesis [27].
RASSF1Amethylationcorrelateswithadecreasedrespon-
siveness to DNA-damaging therapies [100–102]. The DNA
methyltransferase (DNMT) inhibitor zebularine has been
used to eﬀectively reexpress RASSF1A and show an increase
incancercellsensitivitytoradiation-induceddamageinvitro
and in vivo [101] as well as to cisplatin [32]. Dote et al. show-
ed that 48h treatment with zebularine, which corresponded
to the maximum reexpression of RASSF1A increased the
radiosensitivity of PaCa, DU145, and U251 cancer cell lines
by 1.5 times and caused an increased tumour delay in U251
x e n o g r a p hm o d e l si nm i c e[ 101]. A 48h treatment with
zebularine also increased cancer cell sensitivity to DNA
d a m a g ea n da1 6 - f o l dr e d u c t i o ni nI C 50 of cisplatin in resis-
tant ovarian cancer cell lines [32]. Sensitivity of testicular
germ cell tumours to cisplatin could also be enhanced by
another DNMT inhibitor that is in clinical trials, 5-aza-2 -
deoxycytidine [103]. Interestingly, they noted that eﬀective-
ness of the 5-aza-2 -deoxycytidine treatment was dependent
on the level of DNMT3B levels. The higher the DNMT3B
level the greater the eﬀect. The most signiﬁcant target gene
for DNMT3B was shown to be RASSF1A (as mentioned
above) and thus it can be extrapolated that the increase in
sensitivity to cisplatin is due to the reexpression of RASSF1A.
Reexpression of RASSF1A using 5-aza-2 -deoxycytidine or
reintroduction of RASSF1A into the hepatocellular carci-
noma cell line, SMMC-7721, was also shown to increase sen-
s i t i v i t yt oc h e m o t h e r a p e u t i c ss u c ha sﬂ u o r o u r a c i l ,m i t o m y -
cin, and cisplatin [104]. Together these results support a cli-
nically relevant role for RASSF1A in the DNA damage res-
ponse that is backed up by phase I and II clinical trials in
myelodysplasia and leukaemia patients where 5-aza-2 -de-
oxycytidine has shown eﬃcacy both alone and in combina-
tion with the histone deacetylase (HDAC) inhibitor valproic
acid [105, 106]. Therapeutic failure upon RASSF1A loss can
alsobecounteractedbytargetingthedownstreamDNAdam-
age responsive signalling pathway. Direct activation of BAX
via the BH3 mimetic ABT-737 has recently put forward as
a potential treatment for RASSF1A methylated medulloblas-
toma [107]. The role of RASSF1A in checkpoint activation
and maintenance of genomic integrity is highlighted in a
study by Zhang et al. which showed a signiﬁcant increase in
DNA damage caused by aﬂatoxin B1 in tumour tissues where
RASSF1A has been lost due to DNA methylation [108].
8. Other RASSFsandDNA Damage
This paper has concentrated primarily upon the role of
RASSF1 in DNA damage; however, it is worth noting that
other RASSF proteins have also been linked to DNA damage
pathways. The RASSF2 gene resides on chromosome 20. The
gene can be spliced into two very similar proteins RASSF2A
and RASSF2C both of which contain the RA domain and the
SARAH domain. They show 28% identity to RASSF1A and
like RASSF1A, the promoter has been shown to be inactivat-
ed by hypermethylation in primary tumours [109–114].
RASSF2 has been reported to be upregulated in lymphocytes
from individuals exposed to ionising radiation [115].
RASSF2 has also been shown to associate with, and is phos-
phorylated by, MST2 leading to stabilisation of MST2 and
the generation of proapoptotic signals [116].
TheRASSF6 geneis locatedonchromosome 4. While the
expression of RASSF6 is lost in cancer, in silico analysis did
not ﬁnd any CpG islands located near the promoter; there-
fore, it is assumed that this loss is not due to DNA methyla-
tion [117, 118]. RASSF6 is known to activate apoptosis in
both caspase-dependent and -independent mechanisms in
response to TNFα; however, it is unknown whether it is also6 Molecular Biology International
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Figure 2: Cartoon depicting DNA damage activated pathways downstream of RASSF family members. RASSF family members, activated by
DNA damage, signal through various intermediates (primary interaction: light blue and green [involving RASSF1C or RASSF7]; secondary:
orange and tertiary: red) to activate p53, p73, and caspases (purple) to control apoptosis, genome stability, and senescence. Feedback loops
exist from caspases and p53 that further activate the pathways and amplify the signal. RASSF1A can also directly sequester MDM2 leading
to p53 activation. RASSF1C can transfer DNA damage signals from the nucleus to the cytoplasm by activating JNK signalling. RASSF7 acts
as an oncogene inhibiting the activation of JNK.
activated by DNA damage signals [118]. RASSF6 contains
both the RA domain and SARAH domain and like RASSF1A
it has been shown to bind to MOAP-1 [117], which could
be responsible for its induction of apoptosis in response to
TNFα. Unlike other family members, RASSF6 contains a
number of ATM consensus sites (SQ/TQ) upstream of the
RA domain; however it is not clear if these are functional.
RASSF family members eﬃciently form heterodimers
[119]. This provides a potential mechanism through which
additionalRASSFproteinscouldbeinvolvedinDNAdamage
signalling. A heterodimer between RASSF1A and RASSF5A
has been suggested to be important for the interaction of
RASSF1A with Ras [120]. Given that each of the RASSF pro-
teins above is thought to impart its tumour suppressor
function through the MST kinases we could propose that
heterodimeric interactions between RASSF family members
may be important for their DNA damage-induced apoptotic
signalling.
RASSF7 is the best studied N-terminal RASSF protein
and the ﬁrst to be shown to be linked to the DNA damage
response. Located on chromosome 11 close to the H-Ras
gene (HRAS1), it forms part of a microsatellite that is asso-
ciated with increased cancer risk [121–123]. Unlike the ma-
jority of the RASSF family members that are silenced in can-
cer, RASSF7 has been shown to be upregulated in a number
of cancers including pancreatic, endometrial, and ovarian
[124–128]. The upregulation of RASSF7 in cancers suggests
an oncogenic function, the mechanism of which has only
just started to be explored. RASSF7, in concert with N-Ras,
is thought to suppress the activation of JNK in response to
low doses of UV radiation by binding and inhibiting MKK7,
preventing its interaction with JNK. At higher doses of UV,
RASSF7, like RASSF1C, is targeted for degradation through
an ubiquitin-dependent mechanism. This frees MKK7 to
activate a stress response through JNK [129].
9. Conclusion
Ras-association domain containing family members are im-
portant tumour suppressors involved in linking cellular
stressestocellcyclearrestandapoptosis(Figure 2).RASSF1A
is an adaptor protein with three major interaction domains
through which it imparts its functions. Each of these do-
mainsisinvolvedinbindingdiﬀerenteﬀectorproteinsinres-
ponse to DNA damage. The C1 domain binds MDM2 to
stabilise p53 and the RA and SARAH domains are required
to activate the mammalian Hippo pathway. The mammalian
homolog of Hippo, MST1/2, can activate apoptosis in res-
ponse to cellular stresses either directly, in the case of FOXO1
and histone H2B or via LATS1/2. RASSF2, RASSF5, and
RASSF6 which share the RA and SARAH domains with
RASSF1A have also been shown to active MST1/2 to induceMolecular Biology International 7
a p o p t o s i sa sw e l la sb e i n ga b l et oi n d u c ea p o p t o s i si n d e p e n -
dently of the Hippo pathway. LATS1 and 2 have been impli-
cated in apoptosis by stabilising both p53, either directly
through an interaction with MDM2 or indirectly via ASPP1
and stabilising p73 via YAP, in response to DNA damage.
RASSF1ChasbeenshowntobereleasedfromDAXXandp53
upon DNA damage where it can go and transmit the damage
signal from the nucleus to the cytoplasm by activating JNK
signalling. Each of these proteins appears to act both up-
stream and downstream of the “guardian of the genome”
p53 to create a network which feeds back upon itself to en-
hance the DNA damage signaling within the cell. Greater
than 50% of human tumours has either lost or mutated p53.
Disruption of these networks will inactivate p53 and may
contribute to tumourigenesis in a number of the cases where
wild-type p53 is retained. Although not correlated with p53
loss or mutation, RASSF proteins are epigenetically lost in
human cancers by DNA methylation. It has been shown that,
as with p53, loss of RASSF1 expression is associated with
more aggressive tumours and increased resistance to radia-
tion-induced DNA damage and platinum-based drugs.
DMNT inhibitors such as zebularine have been shown to
reexpress RASSF1A and increase the radiosensitivity of these
cancers suggesting that reexpression of RASSF1A and other
silencedRASSFsmaybeapaththroughwhichchemoradiore-
sistant tumours can be combated.
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